Global Pulmonary Arterial Hypertension (PAH) Drugs Market Insights, Forecast to 2025

Description

The global Pulmonary Arterial Hypertension (PAH) Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pulmonary Arterial Hypertension (PAH) Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Pulmonary Arterial Hypertension (PAH) Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pulmonary Arterial Hypertension (PAH) Drugs in these regions.
This research report categorizes the global Pulmonary Arterial Hypertension (PAH) Drugs market by top players/brands, region, type and end user. This report also studies the global Pulmonary Arterial Hypertension (PAH) Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Glaxosmithkline
Novartis
United Therapeutics
AstraZeneca
Merck
Bayer Healthcare
Actelion Pharmaceuticals
Daiichi Sankyo
Northern Therapeutics
Aires Pharmaceuticals
Arena Pharmaceuticals
Berlin Cures
Eiger BioPharmaceuticals
Reata Pharmaceuticals

Market size by Product
Inhalation
Injectables
Oral Administration
Market size by End User
Hospitals
Clinics
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Pulmonary Arterial Hypertension (PAH) Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pulmonary Arterial Hypertension (PAH) Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pulmonary Arterial Hypertension (PAH) Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pulmonary Arterial Hypertension (PAH) Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Pulmonary Arterial Hypertension (PAH) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pulmonary Arterial Hypertension (PAH) Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

TABLE OF CONTENT

Table of Contents

1 Study Coverage
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Product
1.4.2 Inhalation
1.4.3 Injectables
1.4.4 Oral Administration
1.5 Market by End User
1.5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by End User
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size
2.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue 2014-2025
2.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2014-2025
2.2 Pulmonary Arterial Hypertension (PAH) Drugs Growth Rate by Regions
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Regions
2.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers
3.1.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers
3.1.2 Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers
3.1.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers
3.2.1 Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturers
3.4 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Product
4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Product
4.3 Pulmonary Arterial Hypertension (PAH) Drugs Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Breakdown Data by End User

6 North America
6.1 North America Pulmonary Arterial Hypertension (PAH) Drugs by Countries
6.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
6.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Pulmonary Arterial Hypertension (PAH) Drugs by Product
6.3 North America Pulmonary Arterial Hypertension (PAH) Drugs by End User

7 Europe
7.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs by Countries
7.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
7.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs by Product
7.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs by End User

8 Asia Pacific
8.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs by Countries
8.1.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
8.1.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs by Product
8.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs by End User

9 Central & South America
9.1 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs by Countries
9.1.1 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
9.1.2 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs by Product
9.3 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs by End User

10 Middle East and Africa
10.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs by Countries
10.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries
10.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs by Product
10.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs by End User

11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Company Business Overview
11.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.1.5 Pfizer Recent Development
11.2 Glaxosmithkline
11.2.1 Glaxosmithkline Company Details
11.2.2 Company Business Overview
11.2.3 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.2.5 Glaxosmithkline Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Company Business Overview
11.3.3 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.3.5 Novartis Recent Development
11.4 United Therapeutics
11.4.1 United Therapeutics Company Details
11.4.2 Company Business Overview
11.4.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.4.5 United Therapeutics Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 Company Business Overview
11.5.3 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.5.5 AstraZeneca Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Company Business Overview
11.6.3 Merck Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.6.5 Merck Recent Development
11.7 Bayer Healthcare
11.7.1 Bayer Healthcare Company Details
11.7.2 Company Business Overview
11.7.3 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.7.5 Bayer Healthcare Recent Development
11.8 Actelion Pharmaceuticals
11.8.1 Actelion Pharmaceuticals Company Details
11.8.2 Company Business Overview
11.8.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.8.5 Actelion Pharmaceuticals Recent Development
11.9 Daiichi Sankyo
11.9.1 Daiichi Sankyo Company Details
11.9.2 Company Business Overview
11.9.3 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.9.5 Daiichi Sankyo Recent Development
11.10 Northern Therapeutics
11.10.1 Northern Therapeutics Company Details
11.10.2 Company Business Overview
11.10.3 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.10.5 Northern Therapeutics Recent Development
11.11 Aires Pharmaceuticals
11.12 Arena Pharmaceuticals
11.13 Berlin Cures
11.14 Eiger BioPharmaceuticals
11.15 Reata Pharmaceuticals

12 Future Forecast
12.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Regions
12.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Regions 2019-2025
12.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Product
12.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Product 2019-2025
12.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Product 2019-2025
12.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by End User
12.4 North America Pulmonary Arterial Hypertension (PAH) Drugs Forecast
12.5 Europe Pulmonary Arterial Hypertension (PAH) Drugs Forecast
12.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Forecast
12.7 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs Forecast
12.8 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Pulmonary Arterial Hypertension (PAH) Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

Choose License Type

Checkout Inquiry Sample